Brief: Aura Biosciences Announces First Patient Dosed In Early-Stage Study Of Non-Muscle Invasive Bladder Cancer Treatment Candidate
28/09/2022 12:03
Sept 28 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
STUDY
EVALUATING BELZUPACAP SAROTALOCAN (AU-011) FOR TREATMENT OF
NON-MUSCLE INVASIVE BLADDER CANCER
* AURA BIOSCIENCES INC - LOOK FORWARD TO PRESENTING INITIAL
PHASE
1 DATA IN 2023
Source text for Eikon: ID:nBw7VvNRka
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs